Thaulow E, Frøysaker T, Dale J, Vatne K
Medical Department B, Rikshospitalet, Oslo, Norway.
Scand J Thorac Cardiovasc Surg. 1987;21(3):215-20. doi: 10.3109/14017438709106027.
Patients scheduled to receive at least three aortocoronary venous bypass grafts were randomized to active medication or to placebo. The former were given dipyridamole (DP) preoperatively and acetylsalicylic acid (ASA) was added after the operation. For the next 3 months they received DP 75 mg and ASA 325 mg thrice daily. The placebo regimen was identical and the study was conducted with double-blind technique. One patient in each group died. DP-ASA was discontinued in six patients because of gastrointestinal side effects (bleeding peptic ulcer in 2 cases). Angiography after 3 months revealed the patency rate of individual grafts to be 68% in the DP-ASA group and 77% in the placebo group. DP-ASA therefore did not prevent occlusion of aortocoronary venous bypass grafts.
计划接受至少三根主动脉冠状动脉静脉搭桥术的患者被随机分为接受活性药物组或安慰剂组。前者在术前给予双嘧达莫(DP),术后加用阿司匹林(ASA)。在接下来的3个月里,他们每天三次服用75毫克DP和325毫克ASA。安慰剂方案相同,研究采用双盲技术进行。每组各有一名患者死亡。6名患者因胃肠道副作用(2例为消化性溃疡出血)停用DP - ASA。3个月后的血管造影显示,DP - ASA组单个移植物的通畅率为68%,安慰剂组为77%。因此,DP - ASA并不能预防主动脉冠状动脉静脉搭桥移植物的闭塞。